{"classes":[{"categories":[{"measurements":[{"comment":"The upper and lower limits of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"97.0"},{"comment":"The median and upper and lower limits of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper and lower limits of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"86.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"description":"DOR was defined as the time from the first overall response contributing to a confirmed objective response (CR or PR) to the earlier of the participant's death from any cause or first assessment of PD, determined by investigator assessment of radiographic disease assessments per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 milligrams (mg) every 2 weeks (Q2W) beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as intravenous (IV) infusions.","id":"OG000","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG001","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG002","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG003","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kilogram (kg) every 6 weeks (Q6W) beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG004","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG005","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG006","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG007","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG008","title":"Phase 1, Safety Expansion: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG009","title":"Phase 1, Safety Expansion: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG010","title":"Phase 1, Safety Expansion: INCAGN01949 350 mg + Nivolumab 240 mg"}],"paramType":"MEDIAN","populationDescription":"FAS. The confidence interval was calculated using the method of Brookmeyer and Crowley. Only participants with a confirmed CR or PR were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 11.0 months","title":"Phase 1: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"days"}